• 1
    Nayak, RK, Gisclon, LG, Curtin, DA, Benet, LZ. Estimation of the absolute bioavailability of topiramate in humans without intravenous data. J Clin Pharmacol 1994;34:1029.
  • 2
    Easterling, DE, Zakszewski, T, Moyer, MD, Margul, BL, Marriott, TB, Nayak, RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988;29:662.
  • 3
    Doose, DR, Gisclon, LG, Stellar, SM, Riffits, JM, Hills, JF. The effect of food on the bioavailability of topiramate from 100- and 400-mg tablets in healthy male subjects. Epilepsia 1992;33(suppl 3):105.
  • 4
    Doose, DR, Walker, SA, Scott, VV, et al. The comparative bioavailability of topiramate from two investigational paediatric sprinkle formulations relative to a tablet formulation. Epilepsia 1996;37(suppl 5):112.
  • 5
    Doose, DR, Walker, SA, Baldassarre, J. The effect of food on the oral bioavailability of topiramate from an investigational pediatric sprinkle formulation. Epilepsia 1997;38(suppl 3):147.
  • 6
    Perucca, E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996;37(suppl 2):S813.
  • 7
    Doose, DR, Scott, VV, Margul, BL, Marriott, TB, Nayak, RK. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia 1988;29:662.
  • 8
    Wu, WN, Heebner, JB, Streeter, AJ, et al. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant, topiramate in healthy men. Pharm Res 1994;11(suppl):S336.
  • 9
    Johannessen, SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other new antiepileptic drugs. Epilepsia 1997;38(suppl 1):S1823.
  • 10
    Doose, DR. Pharmacokinetic properties of topiramate. In: Dodson, WE, Shorvon, SD, eds. Topiramate: pharmacokinetics, efficacy and tolerability. Royal Society of Medicine Press, London Round Table Series No. 39, 1996:16.
  • 11
    Sachdeo, RC, Sachdeo, SK, Walker, SA, Kramer, LD, Nayak, RK, Doose, DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:77480.
  • 12
    Gisclon, LG, Curtin, CR, Kramer, LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate (TopamaxTM) in epileptic patients on monotherapy, and during combination therapy. Epilepsia 1994;35(suppl 8):54.
  • 13
    Levy, RH, Bishop, F, Streeter, AJ, et al. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Epilepsia 1995;36(suppl 4):47.
  • 14
    Bourgeois, BFD. Drug interaction profile of topiramate. Epilepsia 1996;37(suppl 2):S147.
  • 15
    Rosenfeld, WE, Liao, S, Kramer, LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:32433.
  • 16
    Privitera, MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997;31:116473.
  • 17
    Doose, DR, Walker, SA, Pledger, G, Lim, P, Reife, RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo-controlled trials in outpatients with partial seizures. Epilepsia 1995;36(suppl 3):S158.
  • 18
    Rosenfeld, WE, Doose, DR, Walker, SA, Nayak, RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:31723.
  • 19
    Liao, S, Palmer, M. Digoxin and topiramate drug interaction study in male volunteers. Pharm Res 1993;10(suppl):S405.
  • 20
    Rosenfeld, WE, Doose, DR, Walker, SA, Baldassare, JS, Reife, RA. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999;20:33944.
  • 21
    Glauser, TA, Miles, MV, Tang, P, Clark, P, McGee, K, Doose, DR. Topiramate pharmacokinetics in infants. Epilepsia 1999;40:78891.
  • 22
    Reife, R, Pledger, G, Wu, S. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41:(Suppl 1):S6671.
  • 23
    Gisclon, LG, Riffitts, JM, Sica, DA, Gehr, T, Ruddley, J. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharm Res 1993;10(suppl):S397.
  • 24
    Gisclon, LG, Curtin, CR. The pharmacokinetics (PK) of topiramate (T) in subjects with end-stage renal disease undergoing hemodialysis. Clin Pharmacol Ther 1994;55:196.
  • 25
    Doose, DR, Walker, SA, Venkataramanan, R, Rabinovitz, M, Lever, J. Topiramate pharmacokinetics in subjects with liver impairment. Pharm Res 1994;11(suppl):S446.